4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,953,037 | +163.7% | 153,420 | +274.3% | 0.00% | – |
| Q2 2023 | $740,599 | +85.9% | 40,985 | +76.9% | 0.00% | – |
| Q1 2023 | $398,327 | -37.5% | 23,172 | -19.3% | 0.00% | – |
| Q4 2022 | $637,427 | -62.6% | 28,700 | -86.5% | 0.00% | – |
| Q3 2022 | $1,703,000 | -27.7% | 211,859 | -37.3% | 0.00% | – |
| Q2 2022 | $2,357,000 | +23.9% | 337,742 | +168.4% | 0.00% | – |
| Q1 2022 | $1,902,000 | +107.9% | 125,833 | +201.9% | 0.00% | – |
| Q4 2021 | $915,000 | +145.3% | 41,677 | +201.2% | 0.00% | – |
| Q3 2021 | $373,000 | -43.3% | 13,836 | -49.3% | 0.00% | – |
| Q2 2021 | $658,000 | -22.7% | 27,312 | +39.2% | 0.00% | – |
| Q1 2021 | $851,000 | -60.9% | 19,616 | -62.6% | 0.00% | -100.0% |
| Q4 2020 | $2,175,000 | – | 52,463 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |